This is an excerpt from a post published by NaturalNews.com and is shared in accordance with fair use terms for nonprofit educational purposes.
(Natural News) A new study has found that hydroxychloroquine (HCQ) can increase Wuhan coronavirus (COVID-19) survival rates by up to 200 percent. It also found that when paired with azithromycin (AZM), the drug’s effectiveness was even augmented. Originally for malaria, former President Donald Trump endorsed HCQ as a potential COVID-19 treatment – and received much criticism for it.
The May 31 study published on medRxiv examined patients at the Saint Barnabas Medical Center in New Jersey hospitalized for COVID-19. The patients received different kinds of medical treatments to address COVID-19 such as steroids, tocilizumab, convalescent plasma and HCQ. The study did not include remdesivir as a treatment as it was unavailable at the hospital during the study period.
According to the study authors, patients given HCQ and AZM “had a survival rate 2.9 times [higher] than other patients” when they got both drugs above a certain dose. They added that “combined therapy” of more than three grams of HCQ and more than one gram of AZM “greatly increases survival” of intubated COVID-19 patients.
For the study, the researchers administered a combined treatment of more than three grams of HCQ and more than one gram of AZM to 37 patients. Meanwhile, 218 patients received less than three grams of HCQ and less than one gram of AZM. The 37-patient group recorded a survival rate of 48.6 percent, while the remaining 218 patients registered a low 16.5 percent survival rate.